Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
NCT01103089 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2011-10-12
Summary
The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-03-31
- Primary Completion
- 2010-12-31
- Completion
- 2010-12-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Iressa Expanded Access Program (EAP)
NCT00034879 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
NCT00188617 ·Status: COMPLETED ·Phase: PHASE2
-
Iressa as Second Line Therapy in Advanced NSCLC-Asia
NCT00478049 ·Status: COMPLETED ·Phase: PHASE3
-
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00091156 ·Status: TERMINATED ·Phase: PHASE3
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
NCT00127829 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
NCT00298688 ·Status: COMPLETED ·Phase: PHASE2
-
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
NCT00242801 ·Status: COMPLETED ·Phase: PHASE3
-
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
NCT01000740 ·Status: COMPLETED ·Phase: PHASE4
-
Iressa Case Control Study in Japan
NCT00252759 ·Status: COMPLETED
-
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone
NCT01544179 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
NCT00333294 ·Status: COMPLETED ·Phase: PHASE2
-
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
NCT00770588 ·Status: COMPLETED ·Phase: PHASE4
-
Iressa v BSC (Best Supportive Care) in First Line NSCLC
NCT00259064 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Iressa 2nd Line Phase III Study in Japan
NCT00252707 ·Status: COMPLETED ·Phase: PHASE3
-
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
NCT00322452 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
NCT00104728 ·Status: TERMINATED ·Phase: NA
-
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
NCT00234442 ·Status: TERMINATED ·Phase: PHASE2
-
Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa
NCT01448187 ·Status: COMPLETED
-
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
NCT00455936 ·Status: COMPLETED ·Phase: PHASE3
-
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
NCT00234468 ·Status: TERMINATED ·Phase: PHASE3
-
Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00411047 ·Status: COMPLETED ·Phase: PHASE2
-
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00310154 ·Status: COMPLETED ·Phase: PHASE1
-
Gefitinib Usage and Outcomes in Routine Treatment
NCT01818947 ·Status: COMPLETED
-
Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00029003 ·Status: COMPLETED ·Phase: PHASE2
-
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00075439 ·Status: COMPLETED ·Phase: PHASE2